Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,010 across all filing types
Latest filing 2025-04-29 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于完成注册资本变更登记并换发营业执照的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the completion of the company's registered capital change registration and the issuance of a new business license. It details the increase in registered capital, references prior board and shareholder meetings approving stock incentive plans, and provides updated company registration information. The document is short (1581 characters) and serves as a formal notification of a capital change and related administrative updates. It does not contain financial statements, detailed financial performance, or comprehensive report data. Therefore, it is best classified as a Share Issue/Capital Change announcement (SHA).
2025-04-29 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于康芝药业股份有限公司2023年限制性股票激励计划作废部分限制性股票相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the cancellation of part of a 2023 restricted stock incentive plan by 康芝药业股份有限公司. It includes detailed sections such as definitions, statements, assumptions, approval procedures, and the advisor's opinions on the matter. The document is focused on the financial advisory opinion regarding the stock incentive plan and its cancellation, rather than being a general annual or quarterly financial report. It is not a regulatory filing or announcement but a standalone advisory report. This fits the category of Audit Report / Information (AR), which includes standalone audit or financial advisory reports related to company financial matters but not full annual reports or earnings releases. FY 2025
2025-04-29 Chinese
北京中伦（海口）律师事务所关于康芝药业股份有限公司作废处理部分限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain restricted stocks under a 2023 restricted stock incentive plan of a company. It references relevant laws and regulations, details the approval procedures the company followed, and concludes that the cancellation complies with applicable rules. The document is a legal opinion related to a specific corporate action (cancellation of restricted stock) rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. It is a standalone legal opinion document related to a corporate governance matter involving stock incentives. Therefore, it best fits the category of Regulatory Filings (RNS) as a miscellaneous regulatory/legal document that does not fit other specific categories.
2025-04-29 Chinese
关于预计2025年度日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the expected related party transactions for the fiscal year 2025. It details the nature, amounts, and approval process of these transactions, including board meeting resolutions and independent director opinions. The document is relatively short (3312 characters) and focuses on disclosure of anticipated related party dealings rather than presenting financial statements or comprehensive financial data. It is not an annual or interim report, audit report, or earnings release. It is also not a proxy statement or voting results announcement. The content fits the category of a regulatory announcement about related party transactions, which is typically classified under Regulatory Filings (RNS) as it does not constitute a full financial report or a specific report type but is a compliance disclosure.
2025-04-28 Chinese
关于康芝药业股份有限公司募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) regarding the annual deposit and actual use of raised funds by 康芝药业股份有限公司 for the year 2024. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange concerning the management and use of raised funds. The content includes detailed financial data on the raised funds, their deposit accounts, usage, and related board approvals. It is a specialized audit or attestation report focusing on the use of capital raised by the company, rather than a full annual report or earnings release. The presence of auditor names and certification statements further supports that this is an audit-related report. Therefore, the document fits best under the category of Audit Report / Information (AR). FY 2024
2025-04-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 6th Board of Directors of 康芝药业股份有限公司 on April 25, 2025. It includes approvals of various reports such as the 2024 Annual Report, 2024 Financial Statements, 2024 Profit Distribution Proposal, 2024 Internal Control Self-Evaluation Report, and the 2025 First Quarter Report. The document also references that these reports are disclosed on the official disclosure website (巨潮资讯网) and are subject to shareholder approval at the 2024 Annual General Meeting. The document is not the reports themselves but a formal board meeting resolution announcement summarizing the approval of these reports and other corporate matters. The length is 4742 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full annual or quarterly report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting decisions and management reports approvals rather than containing the full reports or financial data themselves.
2025-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.